Andrea Medford knows the importance of getting a routine eye exam as well as anybody, and in June 2024, it became even ...

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with ...

The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective ...

Pregnancy was not linked with long-term disability outcomes in women with moderately severe multiple sclerosis (MS), registry data suggested. There was no significant difference in time to 6-month ...

The benefit is for people over State Pension age who need help with personal care or supervision due to an illness, ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals that menopause may significantly influence how multiple ...

Successful claimants can now receive either £73.90 or £110.40 per week, depending on the level of support needed. These ...

The 2024 McDonald criteria improve early MS diagnosis with higher sensitivity and accuracy, but lower specificity in real-world settings.

US FDA extends target action date to review Sanofi’s NDA for tolebrutinib in non-relapsing, secondary progressive multiple sclerosis: Paris Tuesday, September 23, 2025, 16:00 Hr ...

The U.S. Food and Drug Administration is delaying by three months its decision on whether or not to approve tolebrutinib for ...

Sanofi SNY announced that the FDA has extended the target action date for its new drug application (NDA) for tolebrutinib by ...